ZEMLIKAFUSP ALFA
UNII EQ9AQ9UV4F
Substance Identification & Data
This profile provides standardized clinical and technical data for Zemlikafusp Alfa, uniquely identified by the FDA Unique Ingredient Identifier (UNII) EQ9AQ9UV4F.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3038191-80-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
EQ9AQ9UV4F
3038191-80-6
N/A
Detailed Substance Profile
Preferred Name
ZEMLIKAFUSP ALFA
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13723
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Zemlikafusp Alfa
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Zemlikafusp Alfa. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Zemlikafusp Alfa
Common Names & Synonyms
Immunoglobulin G1, bispecific, anti-(human CD20 antigen) (human-Mus musculus monoclonal IPH6501 γ1-chain) fusion protein with peptide linker (STGS) fusion protein with immunoglobulin anti-(human natural cytotoxicity triggering receptor 1) (human-Mus musculus single-chain variable fragment VH-peptide linker (synthetic 18-amino acid)-VL) fusion protein with peptide linker ((GSSSS)3) fusion protein with interleukin 2 (recombinant human variant IL2v2A fragment), (225→214′),(231→220′),(234→223′)-tris(disulfide) with immunoglobulin anti-(human CD20 antigen) (human-Mus musculus monoclonal IPH6501 κ-chain) fusion protein with immunoglobulin G1 (human γ1-chain hinge-CH2-CH3 region)
human gamma 1 heavy chain anti-(human B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, leukocyte surface antigen Leu-16, membrane-spanning 4-domains subfamily A member 1, CD20 (MS4A1)) (1-451) [VH (Homo sapiens IGHV3-9*01 -(IGHD) -IGHJ6*01, CDR-Kabat [5.17.13] (31-35.50-66.99-111)) (1-122) -Homo sapiens IGHG1*03 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450), CH3 K452>del (451))]fused at the C-terminus via peptide linker <sup>452</sup>STGS<sup>455</sup> to a humanized variable heavy domain of heavy chain anti-(human natural cytotoxicity triggering receptor 1, lymphocyte antigen 94 homolog, NK cell-activating receptor, natural killer cell p46-related protein, NK-p46, NKp46, hNKp46, CD335 (NCR1, Ly94)) (456-575) [VH (Homo sapiens IGHV1-69*06 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.11] (486-490.505-521.554-564))] fused via peptide linker <sup>576</sup> VEGGSGGSGGSGGSGGVD<sup>593</sup> to humanized variable light domain of light chain anti-(human natural cytotoxicity triggering receptor 1, lymphocyte antigen 94 homolog, NK cell-activating receptor, natural killer cell p46-related protein, NK-p46, NKp46, hNKp46, CD335 (NCR1, Ly94)) (594-700) [V-KAPPA (Homo sapiens IGKV1-33*01 -IGKJ1*01, CDR-Kabat [11.7.9] (617-627.643-649.682-690))] fused at the C-terminus via peptide linker <sup>701</sup>GSSSSGSSSSGS<sup>712</sup> to human interleukin-2 (IL-2, IL2, Uniprot: P60568) fragment variant (4-133, 713-842 in the current sequence, R<sup>38</sup>>A <sup>747</sup>, <sup>F</sup>42</sup>>K<sup>751</sup>, C<sup>125</sup>>A<sup>834</sup>)-disulfide with human VL-CL-G1(h-CH2-CH3) anti-(human B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, leukocyte surface antigen Leu-16, membrane-spanning 4-domains subfamily A member 1, CD20 (MS4A1)) (1'-441') [V-KAPPA (Homo sapiens IGKV3-11*01 -IGKJ5*01, CDR-Kabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (108'-214') -G1(h-CH2-CH3) (215'-441') [Homo sapiens IGHG1*03 (hinge EPKSC 214'-215'>del (215'-224'), CH2 (225'-334'), CH3 (335'-439'), CHS (440'-441'))]]; heterodimer (225-214':231-220':234-223')-trisdisulfide; produced in Chinese hamster ovary (CHO) cells, cell line CHO-M, glycoform alfa
zemlikafusp alfa [INN]
